Clinical Trial Update: Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban [Phase 2]

View source ↗

Summary

Phase 2 study evaluating PER977 (andexanet alfa) for reversing anticoagulation with edoxaban in subjects with steady-state dosing; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anticoagulation Reversal

Drugs mentioned

• PER977

Snippet

Sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | Conditions: Anticoagulation Reversal | Phase 2 | Status: COMPLETED